Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress
6.9.2023 15:00:00 EEST | Business Wire | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.
Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.*
“It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm. “We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.”
“The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC.
Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR.
|
World AMR 2023 Session details |
Congress agenda |
Speakers |
|
Keynote panel Sept. 7th 08:35 EST
|
How can we push AMR to the forefront of preparedness? |
Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm + other invited speakers
|
|
Panel discussion Sept. 7th 11:00–11:30 EST
|
Antibiotic Development stream
The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement
|
Moderator:
Executive Medical Director Debiopharm
Speaker: Dr.L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC
|
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor against Staphylococcus spp., whose methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus ’ essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a Phase 2 trial in bone and joint infections is being conducted in several countries comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first in class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 is administered orally to treat Neisseria gonorrhoeae , the bacteria causing the sexually transmitted disease gonorrhea, a cause of serious and permanent health issues including infertility, ectopic pregnancy, cardiovascular and neurological problems.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
References
[1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635.
[2] Antimicrobial resistance surveillance in Europe 2023–2021 data. www.who.int/europe/publications/i/item/9789289058537
[3] CDC Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[4] COVID-19 U.S. Impact on Antimicrobial Resistance. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
Disclosures
* Speaker disclosures: Dr. McDonald has no relevant financial or non-financial relationships to disclose. The findings and conclusions of this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. Any use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906072351/en/
Contact information
Debiopharm Contact
Dawn Bonine
Head of Communication
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Former Nokia Technologies C-suite Executive Joins Sisvel to Lead Creation of New Ventures Unit27.10.2026 10:04:00 EET | Press release
Stavros Kyris has joined Sisvel to lead the formation of Sisvel Ventures, which has a wide-ranging remit to explore opportunities outside of Sisvel’s core areas of business. Kyris previously held a number of senior roles at Nokia and from 2019 until earlier this year was Chief Strategy, Financial and Operating Officer of Nokia Technologies. Before that, he spent five years as Chief of Staff to Nokia’s CEO, having formerly worked in corporate business development, strategy and M&A at the company. Sisvel Ventures will identify and develop IP-based business projects that do not sit within Sisvel’s established standard essential patent (SEP) pool licensing operation. It will draw on expertise within the broader company while functioning separately from it. Senior Sisvel executives Matteo Sabattini and Leonardo Saroni will join Kyris in building the new unit. “Sisvel Ventures is an exciting endeavour that I am delighted to help launch,” says Kyris. “Sisvel has a reputation for its bold, ent
Institutional Investors and Wealth Advisors Remain Bullish on Private Markets, With a Sharpened Focus on Liquidity: New Report From BBH Investor Services27.10.2026 10:00:00 EET | Press release
Private markets are growing in importance to investors’ overall portfolios, according to new research from Brown Brothers Harriman (BBH) Investor Services today. In BBH’s second annual Private Markets Investor Survey, over a quarter of investors say more than 30% of their investments will be allocated to private markets strategies in the next five years. Most investors (84%) plan to increase their private markets investments within the next two years, with private equity ranking as the top target for new investment (54%), up 16 points from last year, followed by private credit (44%), up 20 points year-over-year. The survey captures the views of 500 institutional investors and wealth advisors in the United States, the United Kingdom, Germany, Switzerland, and Japan. Liquidity emerges as a top priority for investors in this year’s report. Investors signaled that their preferred window for capital deployment in private markets is four to six years, followed by preference for an even short
Unframe Removes Another Barrier Between AI Capabilities and Adoption27.10.2026 10:00:00 EET | Press release
Unframe, the Applied AI Lab, announced its availability on all three leading cloud marketplaces: AWS Marketplace, Google Cloud Marketplace and Microsoft Marketplace. For enterprises, cloud marketplaces have become the preferred channel for discovering and procuring software. AWS, Google Cloud and Microsoft together serve the vast majority of enterprise cloud infrastructure worldwide. Their marketplaces represent a growing share of how organizations purchase technology by consolidating vendor relationships, simplifying contracting and allowing companies to apply existing cloud spend toward new solutions. Being listed across all three is now a key expectation for enterprise-grade software vendors. “Enterprises shouldn’t have to choose between moving quickly on AI and working within the procurement and cloud frameworks they already have,” said Jacquelyn Goldberg, Global VP of Revenue at Unframe. “As an applied AI lab, our job is to close the gap between what AI can do and what enterprises
Ant Group Upgrades LingGuang to 2.0, Turning Its AI Assistant into a Proactive Personal Agent27.10.2026 10:00:00 EET | Press release
Ant Group today announced the launch of LingGuang 2.0, an upgrade that transforms its multimodal AI assistant into a proactive personal agent capable of identifying user needs and managing tasks over time. Moving beyond passive, single-turn interactions, LingGuang 2.0 shifts AI assistance from responding to commands toward continuously identifying needs, following up on tasks, and coordinating everyday affairs on behalf of users. Unlike conventional conversational AI and task-oriented agents, LingGuang 2.0 moves the starting point of AI assistance earlier in the user’s workflow. Instead of waiting for users to issue a command, LingGuang can, with explicit user authorization, draw on connected information and services to spot potential needs, initiate analysis and follow-ups, and alert users when their attention is required. In this way, it evolves from a reactive tool into a personal agent that continuously manages tasks on the user’s behalf. This shift is powered by comprehensive upgr
SES and CANAL+ Strengthen Strategic Partnership Through 204027.10.2026 09:50:00 EET | Press release
SES and CANAL+, the global media and entertainment group, have extended their strategic partnership through 2040 with a multi-year agreement covering capacity across Europe, Africa and the Caribbean. Under the renewed agreement, CANAL+ will leverage SES’s satellite infrastructure across several orbital positions to deliver premium video and pay TV services to a global subscriber base that now exceeds 40 million viewers across 70 countries. "SES has been a trusted partner for more than 30 years, helping us deliver premium content to millions of viewers across Europe and Africa. This new agreement supports our long-term growth and provides the flexibility and reliability required as we continue to expand our international footprint and serve an increasingly diverse subscriber base," said Stéphane Baumier, Chief Technology Officer of CANAL+. "CANAL+ is one of SES's most valued and longest-standing customers. This agreement demonstrates the enduring importance of satellite in reliably deli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom